Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Estrogen and Progesterone Replacement Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Regulation of Cervical Mucus Secretion

NCT02969590
View directory record Official record
Conditions
Fertility, Contraception
Interventions
Leuprolide acetate, Estrogen and Progesterone Replacement, Progestin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 2 Interventional

Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls

NCT00005108
View directory record Official record
Conditions
Atherosclerosis, Healthy, Vascular Disease
Interventions
Estradiol, Progesterone
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Reproductive Hormones on Mood and Behavior

NCT00001322
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Effects of Anorexia Nervosa on Bone Mass in Adolescents

NCT00088153
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Physiologic Estrogen/progesterone, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Perimenopausal Effects of Estradiol on Reward Responsiveness

NCT02255175
View directory record Official record
Conditions
Perimenopausal Depression
Interventions
Estradiol, Progesterone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Postmenopausal Women Estrogen and Progesterone Infusion

NCT00455741
View directory record Official record
Conditions
Postmenopause, Aging
Interventions
Estradiol infusion, Progesterone infusion
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 20, 2026, 5:30 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Vaginal Ecosystem and Network in the United States Study

NCT06472765
View directory record Official record
Conditions
Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Genitourinary Syndrome of Menopause, Lichen Sclerosus, Lichen Planus, Vulvodynia, Endometriosis, Ureaplasma Infections, Cancer, Desquamative Inflammatory Vaginitis
Interventions
Vaginal Swab Collection
Diagnostic Test
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
3,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
20
States / cities
Fullerton, California • Los Angeles, California • Pasadena, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Relationship Between the Menstrual Cycle and Heart Disease in Women

NCT01546454
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 20, 2026, 5:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Women's Health Initiative Memory Study (The WHIMS Study)

NCT00685009
View directory record Official record
Conditions
Dementia Syndromes
Interventions
Estrogen hormone therapy, Estrogen plus progesterone hormone therapy, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
65 Years to 79 Years · Female only
Enrollment
7,525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 20, 2026, 5:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Progestin (Progesterone-Like Hormones) Induced Dysphoria (Depressed Mood, Irritability, Anxiety)

NCT00001770
View directory record Official record
Conditions
Depressive Disorder, Mood Disorder, Psychomotor Agitation
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.

NCT03097120
View directory record Official record
Conditions
Heart Disease
Interventions
0.625 mg of conjugated equine estrogen, 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, placebo tablets
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 20, 2026, 5:30 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2009 · Synced Sep 20, 2026, 5:30 PM EDT
Not yet recruiting No phase listed Observational

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

NCT07795606
View directory record Official record
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 3 Interventional

Heart and Estrogen-Progestin Replacement Study (HERS)

NCT00319566
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
2,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2006 · Synced Sep 20, 2026, 5:30 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 20, 2026, 5:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hormonal Causes of Menstrual-Related Mood Disorders

NCT00100360
View directory record Official record
Conditions
Mood Disorders, Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 20, 2026, 5:30 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism

NCT00565916
View directory record Official record
Conditions
Postmenopausal Syndrome
Interventions
Estrogen, Progesterone, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 2Phase 3 Interventional

Alzheimer's Disease: Therapeutic Potential of Estrogen

NCT00066157
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 90 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Perimenopausal Estrogen Replacement Therapy Study

NCT01308814
View directory record Official record
Conditions
Perimenopause, Menopause, Depression
Interventions
Estradiol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 20, 2026, 5:30 PM EDT
Terminated Phase 3 Interventional

Safety of Estrogens in Lupus: Hormone Replacement Therapy

NCT00000419
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Premarin and Provera
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 20, 2026, 5:30 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency

NCT06851754
View directory record Official record
Conditions
Premature Ovarian Insufficiency
Interventions
Progesterone, Estrogen Patch
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
11 Years to 19 Years · Female only
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 20, 2026, 5:30 PM EDT
Recruiting Phase 3 Interventional

Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

NCT06533865
View directory record Official record
Conditions
FHA (Functional Hypothalamic Amenorrhea)
Interventions
Romosozumab, Placebo, Zoledronic acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 30 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 20, 2026, 5:30 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen Alternatives Study

NCT00108238
View directory record Official record
Conditions
Healthy
Interventions
Estradiol followed by progesterone, Raloxifene
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 20, 2026, 5:30 PM EDT
Recruiting Phase 4 Interventional

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

NCT05282277
View directory record Official record
Conditions
Depression, Psychosis, Anhedonia
Interventions
Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 20, 2026, 5:30 PM EDT